BioSpace News Archive

Lyndra Therapeutics today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder.

Inspirna, Inc.announced today a licensing agreement with Merck KGaA, Darmstadt, Germany, for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic colorectal cancer (mCRC) and SLC6a8 targeting follow-on compounds.

Accord BioPharma, Inc. announced today the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for DMB-3115. DMB-3115 is a proposed biosimilar to STELARA®, a blockbuster drug developed by Janssen Biotech, Inc. and approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Kineta, Inc. announced that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week.

Beijing Avistone Biotechnology Co., Ltd., an innovative biotechnology company focused on precision oncology therapeutics, announced that they had recently completed their Series B financing of 1 billion Chinese yuan.

Napo Pharmaceuticals announced that the United States Patent and Trademark Office on January 2, 2024 issued a new U.S. patent to Napo for methods for treating congenital diarrheal disorders in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that its board of directors has approved a 1-for-20 reverse stock split of the company’s common stock.

Shasqi, Inc. a biotech company whose mission is to make cancer drugs more effective with click chemistry, announced the expansion of its board with the appointment of Pamela M. Klein, M.D., and Mark McCamish M.D., Ph.D.

MOBILion Systems, Inc., a life science tools and instrumentation company, has partnered with The University of Natural Resources and Life Sciences, Vienna, an Agilent Partner Lab, to install its first MOBIE® instrument in Europe.

Nexcella, Inc., announced that effective, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.